Covaryx and Breastfeeding
Studies on Covaryx and breastfeeding suggest that the estrogen hormones in the medication pass through breast milk. These amounts are probably too low to cause any significant problems in a nursing infant, but they could decrease the production and quality of breast milk. Also, the testosterone in Covaryx can cause virilization of female infants. Before using Covaryx, breastfeeding women should consult their healthcare providers.
Covaryx™ (esterified estrogens/methyltestosterone) is a prescription medication used for the treatment of menopause symptoms. The testosterone hormone in the drug could theoretically cause problems in female infants. The estrogen hormones in Covaryx may decrease the quality and quantity of breast milk and can pass through breast milk. Therefore, make sure to check with your healthcare provider before taking Covaryx if you are breastfeeding or planning to breastfeed.
Research suggests that the estrogen hormones in Covaryx pass through breast milk. However, these amounts are probably too low to cause significant or long-lasting problems in nursing infants. More importantly, the estrogen hormones in Covaryx could decrease the production and quality of breast milk. It is for this reason that estrogen-containing medications (including Covaryx, other hormone replacement medications, and many birth control pills) are usually not recommended for women who are breastfeeding.
It is not clear whether the testosterone in Covaryx poses a real danger to female infants. Theoretically, it could cause virilization (masculinization) of female infants, although it is not clear if this truly is a problem.
You should talk with your healthcare provider about Covaryx and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision about Covaryx and breastfeeding that is right for you.